In the third episode of this four-part series, Dr. Justin Abbatemarco and Dr. Albert Aboseif discuss the inspiration behind this abstract.

Show reference:

https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-003990.html

In the second part of this four-part series, Dr. Justin Abbatemarco and Dr. Albert Aboseif discuss treatment options for LGI-1 encephalitis.

Show reference:

https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-003990.html

In part one of this four-part series, Dr. Justin Abbatemarco and Dr. Albert Aboseif discuss how LGI-1 encephalitis typically presents in clinic and how to make the correct diagnosis.

Show reference:

https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-003990.html

Dr. Dan Ackerman and Dr. Phillip Ferdinand discuss the impact smoking has on stroke risk.

Show reference:

https://www.neurology.org/doi/10.1212/WN9.0000000000000003

Dr. Gordon Smith and Dr. Timothy Miller discuss compelling clinical data suggesting that ALS may be a treatable disease for a subset of patients.

In the final part of this three-part series, Dr. Jason Crowell delves into the third issue discussed at NOH, funding for NINDS and the BRAIN Initiative.

Show reference:

https://www.aan.com/advocacy/

In the second part of this three-part series, Dr. Jason Crowell delves into the second issue discussed at NOH, emphasizing the importance of extending telehealth flexibilities.

Show reference:

https://www.aan.com/advocacy/

In the first installment of this three-part series, Dr. Jason Crowell discusses the impact cuts to the Medicare Fee Scheduler has on patient care and the field of neurology.

Show reference:

https://www.aan.com/advocacy/

Dr. Trey Bateman and Dr. Amy Brodtmann discuss referrals for frontal network impairment and FTD, highlighting the most helpful information for reaching a final diagnosis after evaluation.

Show reference:

https://www.neurology.org/doi/10.1212/CPJ.0000000000200360

Dr. Tesha Monteith and Dr. Patricia Pozo-Rosich discuss the latest advancements in headache medicine, focusing on key research findings from 2024.